Insights

Gathering insights about INVENTI…

Similar companies to INVENTI

INVENTI Tech Stack

INVENTI uses 8 technology products and services including LinkedIn Ads, Adobe, Webpack, and more. Explore INVENTI's tech stack below.

LinkedIn Ads
Advertising
Adobe
Audio, Video, Graphics
Webpack
Development
jQuery
Javascript Libraries
Google Maps
Maps
Java
Programming Languages
Python
Programming Languages
Facebook
Widgets

Media & News

Inventiva announces full exercise of Underwriters' Option, bringing proceeds of Offering to approximately $172.5M
Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the underwriters of the previously announced public offering in the United States (the "Offering") of 38,961,038 American Depositary Shares ("ADSs"), each representing one ordinary share of the Company with a nominal value of €0.01, have exercised in full their option (the "Underwriters' Option") to purchase 5,844,155 additional ADSs (the "Additional ADSs"). The additional ADSs are expected to be delivered on November 18, 2025.
Nov 17, 2025 | www.globenewswire.com
Wall Street Week Ahead
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Nov 16, 2025 | seekingalpha.com
Inventiva announces trading resumption of its ordinary shares on Euronext Paris
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 4:30 p.m. (CET).
Nov 13, 2025 | www.globenewswire.com
Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the pricing of its previously announced underwritten public offering, in the United States only, of 38,961,038 new American Depositary Shares ("ADSs"), each representing one new ordinary share of the Company with a nominal value of €0.01, at an offering price of $3.85 per ADS (the "Offering"). Settlement and delivery of the Offering is expected on November 17, 2025, subject to the satisfaction of customary closing conditions.
Nov 13, 2025 | www.globenewswire.com
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), announced today that trading of its ordinary shares on the regulated market of Euronext Paris ("Euronext Paris") will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. (CET). This trading halt takes place in the context of the previously announced public offering by the Company in the United States only of new American Depositary Shares (the "ADSs"), each representing one new ordinary share of the Company with a nominal value of €0.01 (the "Offering"), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Offering.
Nov 13, 2025 | www.globenewswire.com
Inventiva announces launch of public offering
Daix (France), New York City (New York, United States), November 12, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that it plans to offer and sell approximatively $125 million (representing approximately €108 million) of new American Depositary Shares ("ADSs") each representing one new ordinary share of the Company with a nominal value of €0.01, in an underwritten public offering in the United States only (the "Offering"). The Company's ADSs are listed on the Nasdaq Global Market under the ticker symbol "IVA" and the Company's ordinary shares are listed on the regulated market of Euronext in Paris ("Euronext") under the symbol "IVA". All securities to be sold in the Offering will be offered solely by the Company.
Nov 12, 2025 | www.globenewswire.com
Inventiva Announces the Implementation of a New ATM Program
Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) has filed today a shelf registration statement on Form F-3 (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”). The Registration Statement includes a base prospectus and a sales agreement prospectus for a new At-The-Market (“ATM”) program, and allows the Company to issue and sell, from time to time, "at-the-market", including to unsolicited investors who have expressed an interest, ordinary shares in the form of American Depositary Shares (“ADS”). Each ADS represents one ordinary share of Inventiva, for aggregate gross sales proceeds of up to $100 million (subject to a regulatory limit of 30% dilution over a rolling period of 12 months and within the limits of investors' requests expressed in the context of the program), pursuant to the terms of a new sales agreement entered into with Piper Sandler & Co. (“Piper Sandler”), acting as sales agent.
Oct 14, 2025 | www.globenewswire.com

INVENTI's Email Address Formats

INVENTI uses at least 1 format(s):

INVENTI Email Formats	Example	Percentage
First.Last@inventi.cz	John.Doe@inventi.cz	49%
First.Middle@inventi.cz	John.Michael@inventi.cz	1%
First.Last@inventi.cz	John.Doe@inventi.cz	49%
First.Middle@inventi.cz	John.Michael@inventi.cz	1%

Frequently Asked Questions

Where is INVENTI's headquarters located?

INVENTI's main headquarters is located at Táborská 940/31, Praha, 14000, CZ. The company has employees across 3 continents, including EuropeAsiaNorth America.

What is INVENTI's stock symbol?

INVENTI is a publicly traded company; the company's stock symbol is IVA.

What is INVENTI's official website and social media links?

INVENTI's official website is inventi.cz and has social profiles on LinkedIn.

What is INVENTI's NAICS code?

INVENTI's NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does INVENTI have currently?

As of October 2025, INVENTI has approximately 201 employees across 3 continents, including EuropeAsiaNorth America. Key team members include Ceo: P. H.Chief Marketing Officer: P. B.Head Of Web Development: M. K.. Explore INVENTI's employee directory with LeadIQ.

What industry does INVENTI belong to?

INVENTI operates in the IT Services and IT Consulting industry.

What technology does INVENTI use?

INVENTI's tech stack includes LinkedIn AdsAdobeWebpackjQueryGoogle MapsJavaPythonFacebook.

What is INVENTI's email format?

INVENTI's email format typically follows the pattern of First.Last@inventi.cz. Find more INVENTI email formats with LeadIQ.

When was INVENTI founded?

INVENTI was founded in 2011.

INVENTI

Q: What is INVENTI's official website and social media links?

INVENTI's official website is inventi.cz. INVENTI has social profiles on LinkedIn.

Q: How many employees does INVENTI have currently?

INVENTI has approximately 201 employees.

Q: What technology does INVENTI use?

INVENTI's tech stack includes Cloudflare, Next.js, Cognism, Atlassian Jira, JavaScript.

IT Services and IT ConsultingCzech Republic201-500 Employees

We are a technology and consulting software company. Our mission is to translate ideas into the digital world.

INVENTI creates tailor-made solutions for large and medium-sized companies and startups.

We are partners for software and mobile application development such as analysis, design, testing, DevOps and agile project management.